UPLOAD Filing
Akari Therapeutics Plc
Date: July 30, 2025 · CIK: 0001541157 · Accession: 0000000000-25-008047
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289056
Letter
Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed July 29, 2025 File No. 333-289056 Dear Abizer Gaslightwala:
July 30, 2025
Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 30, 2025 Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed July 29, 2025 File No. 333-289056 Dear Abizer Gaslightwala: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq. </TEXT> </DOCUMENT>